– Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) – Pivotal data from Phase 3 PEAK trial in GIST patients selected for oral presentation at 2026 ASCO annual meeting  – Ended 1Q 2026 with $866.4 million in cash, sufficient to fund operations into 2028 WALTHAM, Mass. and BOULDER, Colo., May 05, 2026 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2026. “2026 is shaping up to be a pivotal year for Cogent,” said Andrew Robbins, Cogent’s President and Chief Executive Officer. “We have two NDAs for bezuclastinib under FDA review and expect to...

 Strong Start to the Year on Growing Demand and Continued Focus on Execution of Strategic Initiatives Managing Costs and Mitigating Tariff Impact on Gross Margin MARLBOROUGH, Mass., May 05, 2026 (GLOBE NEWSWIRE) — IPG Photonics Corporation (NASDAQ: IPGP) today reported financial results for the first quarter ended March 31, 2026.    Three Months Ended March 31,(In millions, except per share data and percentages)     2026       2025     ChangeRevenue   $ 265.5     $ 227.8     17 %Gross margin     37.5 %     39.4 %    Operating income (loss)   $ (7.7 )   $ 1.8     NMOperating margin   (2.9)%     0.8 %    Net income   $ 1.6     $ 3.8     (58)%Earnings per diluted share   $ 0.04     $ 0.09     (56)%Non-GAAP Measures*            Adjusted gross margin     37.8 %     40.0 %    Adjusted EBITDA   $ 35.2     $ 32.7     8 %Adjusted...

Announced positive topline induction data from Part A of the Phase 2 SKYLINE trial of SPY001, demonstrating best-in-class efficacy potential and a safety profile consistent with the α4β7 class  Announced over-enrollment and acceleration of topline readout to the third quarter of 2026 of the rheumatoid arthritis (“RA”) sub-study of the Phase 2 SKYWAY basket trial Remain on track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials Further strengthened the balance sheet with $463 million gross proceeds from an underwritten public offering ofcommon stock $1.2 billion in pro forma cash, cash equivalents, and marketable securities as of March 31, 2026, with expected runway into the second half of 2029 WALTHAM, Mass., May 05, 2026 (GLOBE NEWSWIRE) — Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (NASDAQ:SYRE),...

Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated and first patient screened Previous open label trial data presented at SIRS 2026 showed no safety or drug–drug interaction concerns with roluperidone and olanzapine Roluperidone remains the only late-stage drug candidate for this high-need population BURLINGTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported financial and business updates for the first quarter ended March 31, 2026. Business Updates Roluperidone – potentially the First Treatment for Negative Symptoms of SchizophreniaMinerva initiated its global confirmatory Phase 3 clinical trial of roluperidone...

Operating Income of $8.3 Million and Current Accident Year Combined Ratio of 94.9% Demonstrate Continued Underlying Underwriting Profitability on 5.4% Growth in Net Earned Premiums WILMINGTON, Del., May 05, 2026 (GLOBE NEWSWIRE) — Global Indemnity Group, LLC (Nasdaq: GBLI) (the “Company”) today reported financial results for the three months ended March 31, 2026. Operating income was $8.3 million, or $0.57 per share, compared to an operating loss of $4.1 million, or ($0.30) per share in 2025. Net income available to common shareholders was $4.1 million, or $0.29 per share, compared to a net loss of $4.1 million, or ($0.30) per share in 2025. Current accident year underwriting income increased to $5.5 million in 2026, growth of 4% over 2025 excluding the California Wildfires, with a 54.8% loss ratio and a 94.9% combined...

OAK BROOK, Ill., May 05, 2026 (GLOBE NEWSWIRE) — Portillo’s Inc. (“Portillo’s” or the “Company”) (NASDAQ: PTLO), the one-of-a-kind restaurant concept known for its menu of Chicago-style favorites, today reported financial results for the first quarter ended March 29, 2026. First Quarter 2026 Performance Highlights (vs. First Quarter 2025):Total revenue of $182.6 million, an increase of 3.5% or $6.2 million Same-restaurant sales decrease of -0.1% Operating income of $4.5 million, a decrease of $5.9 million Net loss of $0.5 million, a decrease of $4.5 million from net income of $4.0 million Restaurant-Level Adjusted EBITDA(1) of $34.8 million, a decrease of $1.8 million Adjusted EBITDA(1) of $18.5 million, a decrease of $2.8 million(1) Restaurant-Level Adjusted EBITDA and Adjusted EBITDA are non-GAAP measures. Please see definitions...

OTTAWA, Ontario, May 05, 2026 (GLOBE NEWSWIRE) — Telesat (Nasdaq and TSX: TSAT), one of the world’s largest and most innovative satellite operators, today announced its financial results for the three month period ended March 31, 2026. All amounts are in Canadian dollars and reported under IFRS® Accounting Standards unless otherwise noted. “I’m pleased with Telesat’s performance in the first quarter of 2026, as the company made significant strides on a number of fronts,” commented Dan Goldberg, Telesat’s President and CEO. “Our GEO results are tracking to our expectations, and we continue to make strong progress on the development of the Telesat Lightspeed constellation. During the quarter, we held further design reviews with our satellite and launch vehicle dispenser manufacturers and progressed our work on user terminals, network...

BRENTWOOD, Tenn., May 05, 2026 (GLOBE NEWSWIRE) — Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, today announced results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights (All comparisons are year-over-year unless otherwise noted)Revenue increased 4.5% for the first quarterSame-facility revenues increased 4.4% for the first quarter Same-facility cases increased 0.6% for the first quarterNet loss attributable to Surgery Partners, Inc. was $35.9 million for the first quarterAdjusted EBITDA was $102.3 million for the first quarter2026 GuidanceFull year 2026 revenue guidance reaffirmed to be in the range of $3.35 billion to $3.45 billion and Adjusted EBITDA of at least $530 millionEric Evans, Chief...

As recently announced, tovecimig (DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement in progression-free survival (PFS) versus paclitaxel alone as well as clear signals of a survival benefit in a Phase 2/3 study of patients with biliary tract cancer (BTC); tovecimig previously met the primary endpoint of overall response rate (ORR).  Tovecimig received Orphan Drug Designation in April and the Company intends to meet with the FDA in advance of its planned BLA submission later this year. The Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific antibody) has been selected for a poster presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, highlighting three deep responses (TNBC, NSCLC, HL) in patients treated in the post-checkpoint...

NXP900 Phase 1b clinical program continues to enroll patients at select sites in the US NXP900 preclinical presentations at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting” further support the clinical development strategyFORT LEE, N.J., May 05, 2026 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the first quarter of 2026 and provided an update on recent business progress. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “2026 is off to a good start for Nuvectis as we advance the NXP900 Phase...